Interim report
Page 1
OneSource Specialty Pharma Limited Formerly Stelis Biopharma Limited CIN: L74140MH2007PLC432497info@onesourcecdmo.com | www.onesourcecdmo.com Corporate Oĸce: Star 1, Opp IIM Bangalore, Bilekahalli, BannerghaƩa Road, Bengaluru – 560076, India T: +91 80 6784 0738 Registered Oĸce: Cyber One, Unit No. 902, Sector 30A, Plot No - 4 & 6, Vashi, Navi Mumbai - 400703, India T: +91 22 2789 2924 Date: October 27, 2026 BSE Limited Phiroze Jeejeebhoy Towers Dalal Street, Mumbai- 400001 Scrip Code: 544292 National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai – 400 051 Symbol: ONESOURCE Dear Sir/ Madam, Subject: Outcome of Board Meeting – Un-audited Financial Results (Consolidated & Standalone) for quarter ended September 30, 2026 Reg: Regulation 30 and 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”) We are pleased to enclose the Un-audited Financial Results (Standalone and Consolidated) of the Company along with Limited Review Report of the Statutory Auditors for the quarter and half year ended September 30, 2026, as approved by the Board of Directors of the Company at their meeting held today i.e., October 27, 2026. The Board Meeting commenced at 09:00 hrs IST and concluded at 10:00 hrs IST. You are requested to kindly take the same on record. For and on behalf of OneSource Specialty Pharma Limited Trisha A Company Secretary and Compliance Officer Membership Number: A47635 Encl. as above A. TRISHA Digitally signed by A. TRISHA Date: 2026.10.27 10:01:40 +05'30'
Page 2
B S R & Co. LLP Chartered Accountants Embassy Golf Links Business Park Pebble Beach, B Block, 3rd Floor No. 13/2, off Intermediate Ring Road Bengaluru - 560 071, India Telephone: +91 80 4682 3000 Fax: +91 80 4682 3999 Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 2 Limited Review Report on unaudited standalone financial results of OneSource Specialty Pharma Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of OneSource Specialty Pharma Limited 1. We have reviewed the accompanying Statement of unaudited standalone financial results of OneSource Specialty Pharma Limited (hereinafter referred to as “the Company”) for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 (“the Statement”). 2. This Statement, which is the responsibility of the Company’s management and approved by its Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “Interim Financial Reporting” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (“Listing Regulations”). Our responsibility is to issue a report on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. 4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement. 5. The standalone financial results of the Company for the year ended 31 March 2026 were audited by the predecessor auditor whose report dated 13 May 2026 had expressed an unmodified opinion. The standalone financial results of the Company for the corresponding quarter ended 30 September 2025 and the corresponding period from 01 April 2025 to 30 September 2025 were reviewed by the predecessor auditor whose report dated 11 November 2025 had expressed an unmodified conclusion.
Page 3
BSR&C o .L L P Limited Review Report (Continued) OneSource Specialty Pharma Limited Page 2 of 2 6. The standalone financial results of the Company for the three months ended 30 June 2026 were reviewed by the predecessor auditor whose report dated 24 July 2026 had expressed an unmodified conclusion. For B S R & Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 G Prakash Partner Bengaluru Membership No.: 099696 27 October 2026 UDIN:26099696KZPTYJ6797 G PRAKAS H Digitally signed by G PRAKASH Date: 2026.10.27 09:24:48 +05'30'
Page 4
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Standalone Financial Results for the quarter and six months ended September 30, 2026 Rs. in Million, except per share data Year ended September 30, 2026 June 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 March 31, 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Income 1 Revenue from operations 5,144.96 4,464.71 3,751.87 9,609.67 6,961.99 14,053.81 2 Other income 9.23 37.87 30.36 47.10 82.91 150.08 3 Total income (1+2) 5,154.19 4,502.58 3,782.23 9,656.77 7,044.90 14,203.89 4 Expenses (a) Cost of materials consumed 1,096.48 422.97 652.17 1,519.45 1,160.65 2,525.42 (b) Changes in inventories of finished goods and work-in-progress (48.20) 11.33 (100.59) (36.87) (51.22) 32.74 (c) Consumables 426.06 988.88 558.24 1,414.94 925.26 1,887.19 (d) Employee benefits expense 772.88 683.93 590.46 1,456.81 1,171.98 2,404.47 (e) Finance costs (refer note 4) 341.81 305.17 333.08 646.98 603.39 1,205.76 (f) Depreciation and amortisation expense 390.43 361.77 342.07 752.20 674.91 1,367.95 (g) Other expenses 1,312.81 1,216.28 1,035.79 2,529.09 1,940.77 4,514.06 Total expenses (4) 4,292.27 3,990.33 3,411.22 8,282.60 6,425.74 13,937.59 5 Profit before exceptional items and tax (3-4) 861.92 512.25 371.01 1,374.17 619.16 266.30 6 Exceptional items - gain / (loss) (net) (refer note 3) - - - - - (54.20) 7 Profit before tax (5+6) 861.92 512.25 371.01 1,374.17 619.16 212.10 8 Income tax expense Current tax - - - - - - Deferred tax - - - - - - Total tax expense - - - - - - 9 Profit after tax (7-8) 861.92 512.25 371.01 1,374.17 619.16 212.10 10 Other Comprehensive Income Items that will not be reclassified to statement of profit and loss - Remeasurements of post-employment benefit obligations- gain - - - - - 4.57 Total other comprehensive income - - - - - 4.57 11 Total comprehensive income for the period/year (9+10) 861.92 512.25 371.01 1,374.17 619.16 216.67 12 Paid-up equity share capital (of Rs. 1/- each) 114.67 114.64 114.52 114.67 114.52 114.62 13 Reserves (Other Equity) 59,387.60 14 Earnings per share (of Rs. 1/- each) : (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) - Basic 7.52 4.47 3.24 11.98 5.41 1.85 - Diluted 7.51 4.47 3.24 11.98 5.40 1.85 See accompanying notes to the Statement of Unaudited Standalone Financial Results for the quarter and six months ended Septembe r 30, 2026 Sl No Six months endedQuarter ended Particulars
Page 5
CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Standalone Financial Results for the quarter and six months ended September 30, 2026 Standalone Balance Sheet as at September 30, 2026 Rs. in Million As at September 30, 2026 As at March 31, 2026 (Unaudited) (Audited) I 9,546.96 7,273.99 (b) Right of use assets 2,329.97 1,984.58 1,408.25 3,138.96 (d) Goodwill 19,761.42 19,761.42 2,965.97 2,955.84 1,701.18 1,546.78 29,257.16 29,257.15 (ii) Security deposits 159.26 170.89 (iii) Other financial assets 11.29 - 2,739.26 2,100.69 Total non-current assets 69,880.72 68,190.30 II (a) Inventories 4,458.61 4,389.58 (i) Investments 56.34 54.59 (ii) Trade receivables 10,812.85 7,352.45 86.25 280.59 (iv) Bank balances other than (iii) above 187.55 618.92 (v) Other financial assets 100.67 164.59 (c) Other current assets 1,698.59 1,709.57 Total current assets 17,400.86 14,570.29 Total assets (I+II) 87,281.58 82,760.59 B. I (a) Equity share capital 114.67 114.62 (b) Other equity 60,765.30 59,387.60 Total Equity 60,879.97 59,502.22 II Liabilities 1 5,842.25 1,960.19 2,652.29 2,187.93 14.23 1.32 199.04 182.52 (c) Other non-current liabilities 58.26 10.26 Total Non-current liabilities 8,766.07 4,342.22 2 8,994.05 10,802.77 59.86 88.50 (A) total outstanding dues of micro and small enterprises 170.22 219.66 (B) total outstanding dues of creditors other than micro and small enterprises 5,601.49 3,799.73 1,203.75 1,232.17 1,468.52 2,645.64 137.65 127.68 Total Current liabilities 17,635.54 18,916.15 Total liabilities (1+2) 26,401.61 23,258.37 Total Equity and liabilities (I+II) 87,281.58 82,760.59 See accompanying notes to the Statement of Unaudited Standalone Financial Results for the quarter and six months ended Septembe r 30, 2026 (i) Investments OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India Particulars ASSETS Non-current assets (a) Property, plant and equipment (c) Capital work in progress (e) Other intangible assets (f) Intangible assets under development (g) Financial assets (b) Provisions (h) Other non-current assets Current assets (b) Financial assets (iii) Cash and cash equivalents EQUITY AND LIABILITIES Equity Non-current liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease liabilities (iii) Other financial liabilities (b) Other current liabilities (c) Provisions Current liabilities (a) Financial Liabilities (i) Borrowings (ii) Lease liabilities (iii) Trade payables (iv) Other financial liabilities
Page 6
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Standalone Financial Results for the quarter and six months ended September 30, 2026 Standalone Statement of Cash Flows for the six months ended September 30, 2026 Rs. in Million September 30, 2026 September 30, 2025 (Unaudited) (Unaudited) A. Cash flow from operating activities Profit before tax for the period ended 1,374.17 619.16 Adjustments for: Depreciation and amortisation expenses 752.20 674.91 Finance costs 646.98 603.39 Interest income (27.45) (67.75) Share based payment expenses (4.00) 17.29 Gain on termination of lease (6.63) - Loss on sale of property, plant and equipment 23.75 1.69 Unrealised exchange (gain)/ loss (net) 103.62 (219.02) Profit on sale of investments/ dividend from MF (1.74) (0.50) Loss allowance on trade receivables 37.36 11.32 1,524.09 1,021.33 Operating profit before working capital changes 2,898.26 1,640.49 Changes in working capital: Adjustments for (increase) / decrease in operating assets: Trade receivables (3,587.11) (2,058.85) Other assets (financial & non-financial) (157.04) (14.19) Decrease / (increase) in inventories (69.03) (1,673.78) Adjustments for increase / (decrease) in operating liabilities: Trade payables 1,738.05 1,275.67 Other liabilities (financial & non-financial) (1,068.33) 196.43 (3,143.46) (2,274.72) Cash generated from operations (245.20) (634.23) Income taxes (paid)/refund (7.89) 67.38 Net cash flow generated from/ (used in) operating activities (A) (253.09) (566.85) B. Cash flow from investing activities Purchases of property, plant and equipment (including CWIP and capital advances) (1,651.90) (2,566.70) Proceeds from sale of property, plant and equipment 7.68 0.04 Investments in others - (14.74) Investments in Subsidiaries (0.01) - Proceeds from redemption / (contribution to) of margin money deposits 431.37 852.25 Interest received 6.48 32.39 Net cash used in investing activities (B) (1,206.38) (1,696.76) C. Cash flow from financing activities Proceeds from issue of fresh equity shares 4.41 30.35 Repayment of related party loan - (32.50) Proceeds/(repayment) of short term borrowings (net) 1,158.65 517.16 Proceeds of long-term borrowings 3,258.94 2,741.25 Repayment of long-term borrowings (2,339.94) (352.88) Lease Payments (122.16) (110.88) Interest paid (693.87) (466.52) Net cash flow from financing activities (C) 1,266.03 2,325.98 Six months ended Particulars
Page 7
September 30, 2026 September 30, 2025 (Unaudited) (Unaudited) Six months ended Particulars Net increase / (decrease) in ca sh and cash equivalents (A+B+C) (193.44) 62.37 Cash and cash equivalents at the beginning of the period 307.20 920.86 Cash and cash equivalents at the end of the period 113.76 983.23 Reconciliation of cash and cash equivalents with the Standalone Balance Sheet: Cash and cash equivalents as per Balance Sheet 86.25 957.38 Liquid Mutual Funds 27.51 25.85 Cash and cash equivalents at the end of the period * 113.76 983.23 * Cash and cash equivalents comprises: Cash on hand 0.53 0.84 Balances with banks - in current accounts 85.72 956.54 Liquid Mutual Funds 27.51 25.85 Total 113.76 983.23 See accompanying notes to the Statement of Unaudited Standalone Financial Results for the quarter and six months ended Septembe r 30, 2026
Page 8
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no.-4 & 6, Sector 30A, Vashi, Navi Mumbai - 400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Notes to the Statement of Unaudited Standalone Financial Results for the quarter and six months ended September 30, 2026 1 2 3 Rs. in Million Year ended September 30, 2026 June 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 March 31, 2026 Employees' one-time mutual separation settlement - - - - - (41.47) Gratuity and Compensated absences impact under new Labour Codes - - - - - (12.73) Total - - - - - (54.20) 4 5 6 7 For and on behalf of Board of Directors of OneSource Specialty Pharma Limited Neeraj Sharma Managing Director DIN : 09402652 Place : Bengaluru Date : October 27, 2026 Figures for the previous periods, wherever necessary, have been regrouped/reclassified to conform to the current period's presentation. The Ministry of Corporate Affairs (MCA), vide its notification dated 13 August 2025, amended Ind AS 1 with respect to breach of covenants. Under the amended requirements the relief relating to “covenant waivers obtained after the balance sheet date but before the date of financial statements issuance” has been withdrawn for accounting periods beginning on or after 1 April 2026, and the amendment is required to be applied retrospectively to the comparative period ended March 31, 2026. Pursuant to the aforesaid amendment, the Company has, in these financial results, reclassified its comparative borrowings as at March 31, 2026 amounting to Rs. 3,676.84 million from non-current financial liabilities to current financial liabilities, considering that waiver relating to tw o of its borrowing facilities was obtained after March 31, 2026 but before the issuance of the financial statements for the year ended March 31, 2026. This reclassification impacts only the presentation of the aforesaid borrowings and has no effect on total borrowings, net worth, profit after tax, earnings per share or cash flows of the Company, or on the presentation of its audited financial statements as on and for the year ended March 31, 2026. Particulars Six months ended During the previous year ended March 31, 2026, the Company has capitalised borrowing costs attributable to qualifying assets classified under Capit al Work-in-Progress (CWIP), in accordance with Ind AS 23, Borrowing Costs. The determination of borrowing costs eligible for capitalisation was completed based on detailed project-level assessments undertaken as part of the year- end closing process, including technical and operational evaluations of the activities necessary to prepare the assets for their intended use. Give nt h e long gestation period and complexity of the projects, such assessments are concluded upon completion of the requisite evaluations. Accordingly, borrowing costs amounting to Rs. 186.09 million have been capitalised for the year ended March 31, 2026 (Rs. 103.40 million relates to the previous quarters of the same financial year) resulting in a corresponding reduction in finance costs for the year ended March 31, 2026 and an increase in Capital Work-in-Progress. The Company publishes these Unaudited Standalone Financial Results along with Unaudited Consolidated Financial Results. In accordance with Ind AS 108, 'Operating Segments', the Company has disclosed the segment information in the Unaudited Consolidated Financial Results. In terms of Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Requirements"), as amended, the Statement of Unaudited Standalone Financial Results for the quarter and six months ended September 30, 2026 ("Statement") of OneSource Specialty Pharma Limited ('the Company') has been reviewed by the Audit Committee at their meeting held on October 26, 2026 and approved by the Board of Directors at their meeting held on October 27, 2026. The aforesaid results have been reviewed by the statutory auditor of the Company, who has issued an unmodified report in respect of the limited review for the quarter and six months ended September 30, 2026. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act, 2013, as amended, read with relevant rules thereunder and in terms of Listing Requirements, as amended. Exceptional items - gain / (loss) (net) Quarter ended Neeraj Sharma Digitally signed by Neeraj Sharma Date: 2026.10.27 09:05:21 +05'30'
Page 9
B S R & Co. LLP Chartered Accountants Embassy Golf Links Business Park Pebble Beach, B Block, 3rd Floor No. 13/2, off Intermediate Ring Road Bengaluru - 560 071, India Telephone: +91 80 4682 3000 Fax: +91 80 4682 3999 Registered Office: B S R & Co. (a partnership firm with Registration No. BA61223) converted into B S R & Co. LLP (a Limited Liability Partnership with LLP Registration No. AAB-8181) with effect from October 14, 2013 14th Floor, Central B Wing and North C Wing, Nesco IT Park 4, Nesco Center, Western Express Highway, Goregaon (East), Mumbai - 400063 Page 1 of 2 Limited Review Report on unaudited consolidated financial results of OneSource Specialty Pharma Limited for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 pursuant to Regulation 33 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended To the Board of Directors of OneSource Specialty Pharma Limited 1. We have reviewed the accompanying Statement of unaudited consolidated financial results of OneSource Specialty Pharma Limited (hereinafter referred to as “the Parent”), and its subsidiaries (the Parent and its subsidiaries together referred to as “the Group”) for the quarter ended 30 September 2026 and year to date results for the period from 01 April 2026 to 30 September 2026 (“the Statement”), being submitted by the Parent pursuant to the requirements of Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("Listing Regulations"). 2. This Statement, which is the responsibility of the Parent’s management and approved by the Parent’s Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 “ Interim Financial Reporting ” (“Ind AS 34”), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to express a conclusion on the Statement based on our review. 3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 “Review of Interim Financial Information Performed by the Independent Auditor of the Entity”, issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion. We also performed procedures in accordance with the circular issued by the Securities and Exchange Board of India under Regulation 33(8) of the Listing Regulations, to the extent applicable. 4. The Statement includes the results of the following entities: i. OneSource Specialty Pharma Limited ii. OneSource Specialty PTE. Limited iii. Strides Pharma Services Private Limited iv. Biolexis Private Limited v. OneSource Specialty Pharma Inc. vi. OneSource Softgels PTE. Ltd. vii. Biolexis PTE. Ltd. 5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Indian Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the Listing Regulations, including the manner in which it is to be disclosed, or that it contains any material misstatement.
Page 10
BSR&C o .L L P Limited Review Report (Continued) OneSource Specialty Pharma Limited Page 2 of 2 6. The consolidated financial results of the Group for the year ended 31 March 2026 were audited by the predecessor auditor whose report dated 13 May 2026 had expressed an unmodified opinion. The consolidated financial results of the Group for the corresponding quarter ended 30 September 2025 and the corresponding period from 01 April 2025 to 30 September 2025 were reviewed by the predecessor auditor whose report dated 11 November 2025 had expressed an unmodified conclusion. 7. The consolidated financial results of the Group for the three months ended 30 June 2026 were reviewed by the predecessor auditor whose report dated 24 July 2026 had expressed an unmodified conclusion. 8. The Statement includes the interim financial information of 5 Subsidiaries which have not been reviewed, whose interim financial information reflect total assets (before consolidation adjustments) of Rs. 600.35 million as at 30 September 2026 and total revenues (before consolidation adjustments) of Rs. 40.66 million and Rs. 79.71 million, total net profit / (loss) after tax (before consolidation adjustments) of Rs. 20.26 million and Rs. 40.52 million and total comprehensive income (before consolidation adjustments) of Rs. 20.26 million and Rs. 40.52 million, for the quarter ended 30 September 2026 and for the period from 01 April 2026 to 30 September 2026 respectively, and cash outflows (net) (before consolidation adjustments) of Rs. 21.01 million for the period from 01 April 2026 to 30 September 2026 as considered in the Statement. According to the information and explanations given to us by the Parent’s management, these interim financial information are not material to the Group. Our conclusion is not modified in respect of this matter. For B S R & Co. LLP Chartered Accountants Firm’s Registration No.:101248W/W-100022 G Prakash Partner Bengaluru Membership No.: 099696 27 October 2026 UDIN:26099696BJAYNG7426 G PRAKASH Digitally signed by G PRAKASH Date: 2026.10.27 09:23:53 +05'30'
Page 11
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 Rs. in Million, except per share data Year ended September 30, 2026 June 30, 2026 September 30, 2025 September 30, 2026 September 30, 2025 March 31, 2026 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) Income 1 Revenue from operations 5,162.42 4,490.23 3,757.63 9,652.65 7,030.33 14,215.90 2 Other income 9.54 38.02 30.36 47.56 83.04 150.22 3 Total income (1+2) 5,171.96 4,528.25 3,787.99 9,700.21 7,113.37 14,366.12 4 Expenses (a) Cost of materials consumed 1,096.48 422.97 653.34 1,519.45 1,161.82 2,481.53 (b) Changes in inventories of finished goods and work-in-progress (48.20) 11.33 (100.59) (36.87) (5.02) 78.94 (c) Consumables 426.06 988.88 558.24 1,414.94 883.38 1,886.02 (d) Employee benefits expense 775.80 686.80 593.41 1,462.60 1,177.79 2,422.53 (e) Finance costs (refer note 7) 345.62 308.09 339.63 653.71 614.41 1,221.85 (f) Depreciation and amortisation expense 750.51 717.46 698.27 1,467.97 1,376.30 2,790.93 (g) Other expenses 1,279.37 1,146.78 988.28 2,426.15 1,862.57 4,304.66 Total expenses (4) 4,625.64 4,282.31 3,730.58 8,907.95 7,071.25 15,186.46 5 Profit/(loss) before exceptional items and tax (3-4) 546.32 245.94 57.41 792.26 42.12 (820.34) 6 Exceptional items - gain / (loss) (net) (refer note 4) (17.67) (43.00) - (60.67) (28.70) (99.27) 7 Profit/(Loss) before tax (5+6) 528.65 202.94 57.41 731.59 13.42 (919.61) 8 Income tax expense Current tax 2.91 2.81 8.69 5.72 10.70 22.12 Deferred tax (49.10) (49.84) (56.13) (98.94) (100.27) (203.70) Total tax expense (46.19) (47.03) (47.44) (93.22) (89.57) (181.58) 9 Profit/(Loss) after tax (7-8) 574.84 249.97 104.85 824.81 102.99 (738.03) 10 Other Comprehensive Income Items that will not be reclassified to statement of profit and loss - Remeasurements of post-employment benefit obligations- gain - - - - - 4.57 - Fair Value Changes on Equity Investments (FVOCI) gain/(loss) 0.28 12.44 - 12.72 - (71.19) Items that may be reclassified to statement of profit and loss 31.37 23.51 58.18 54.88 88.31 227.20 Total other comprehensive income 31.65 35.95 58.18 67.60 88.31 160.58 11 Total comprehensive income/(loss) for the period/year (9+10) 606.49 285.92 163.03 892.41 191.30 (577.45) 12 Paid-up equity share capital (of Rs. 1/- each) 114.67 114.64 114.52 114.67 114.52 114.62 13 Reserves (Other Equity) 58,198.27 14 Earnings/ (Loss) per share (of Rs. 1/- each): (not annualised) (not annualised) (not annualised) (not annualised) (not annualised) (annualised) - Basic 5.01 2.18 0.92 7.19 0.90 (6.44) - Diluted 5.01 2.18 0.91 7.19 0.90 (6.44) See accompanying notes to the Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 Sl No Particulars Quarter ended - Exchange differences in translating the financial statements of foreign operations Six months ended
Page 12
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 Consolidated Balance Sheet as at September 30, 2026 Rs. in Million Particulars As at September 30, 2026 As at March 31, 2026 (Unaudited) (Audited) A. ASSETS I Non-current assets (a) Property, plant and equipment 9,546.96 7,273.99 (b) Right of use assets 2,329.97 1,984.58 (c) Capital work in progress 1,408.25 3,138.96 (d) Goodwill 38,275.31 38,275.31 (e) Other intangible assets 12,081.74 12,639.91 (f) Intangible assets under development 2,218.37 2,154.25 (g) Financial assets (i) Investments 115.37 102.16 (ii) Security deposits 159.26 170.89 (iii) Other financial assets 11.29 - (h) Other non-current assets 2,739.44 2,100.69 Total non-current assets 68,885.96 67,840.74 II Current assets (a) Inventories 4,458.61 4,389.58 (b) Financial assets (i) Investments 56.34 54.59 (ii) Trade receivables 10,329.10 6,902.22 (iii) Cash and cash equivalents 141.79 356.76 (iv) Bank balances other than (iii) above 187.55 618.92 (v) Other financial assets 100.67 164.59 (c) Other current assets 1,700.80 1,772.74 Total current assets 16,974.86 14,259.40 Total assets (I+II) 85,860.82 82,100.14 B. EQUITY AND LIABILITIES I Equity (a) Equity share capital 114.67 114.62 (b) Other equity 59,094.21 58,198.27 Total Equity 59,208.88 58,312.89 II Liabilities 1 Non-current liabilities (a) Financial Liabilities (i) Borrowings 5,842.25 1,960.19 (ii) Lease liabilities 2,652.29 2,187.93 (iii) Other financial liabilities 14.23 1.32 (b) Provisions 199.04 182.52 (c) Deferred tax liabilities (net) 1,249.74 1,348.50 (d) Other non-current liabilities 58.26 10.26 Total Non-current liabilities 10,015.81 5,690.72 2 Current liabilities (a) Financial Liabilities (i) Borrowings 8,994.05 10,802.77 (ii) Lease liabilities 59.86 88.50 (iii) Trade payables (A) total outstanding dues of micro and small enterprises 170.22 219.66 (B) total outstanding dues of creditors other than micro and small enterprises 5,185.04 3,525.85 (iv) Other financial liabilities 605.92 666.05 (b) Current tax liabilities 13.00 18.99 (c) Other current liabilities 1,468.94 2,645.98 (d) Provisions 139.10 128.73 Total Current liabilities 16,636.13 18,096.53 Total liabilities (1+2) 26,651.94 23,787.25 Total Equity and liabilities (I+II) 85,860.82 82,100.14 See accompanying notes to the Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026
Page 13
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, We bsite : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 Consolidated Statement of Cash Flows for the period and six months ended September 30, 2026 Rs. in Million September 30, 2026 September 30, 2025 (Unaudited) (Unaudited) A Cash flow from operating activities Profit before tax for the period 731.59 13.42 Adjustments for: Depreciation and amortisation expenses 1,467.97 1,376.30 Finance costs 653.71 614.41 Interest income (27.60) (67.88) Share based payment expenses (4.00) 17.29 Gain on termination of lease (6.63) - Loss on sale of property, plant and equipment 23.75 1.69 Loss allowance on trade receivables 89.02 11.32 Unrealised exchange (gain)/ loss (net) 99.69 (208.48) Profit on sale of investments/ dividend from MF (1.74) (0.50) 2,294.17 1,744.15 Operating profit before working capital changes 3,025.76 1,757.57 Changes in working capital: Adjustments for (increase) / decrease in operating assets: Trade receivables (3,605.25) (1,636.53) Other assets (financial & non-financial) (81.61) 4.25 Decrease / (increase) in inventories (69.03) (1,672.67) Adjustments for increase / (decrease) in operating liabilities: Trade payables 1,655.18 1,145.95 Other liabilities (financial & non-financial) (1,097.87) 55.13 (3,198.58) (2,103.87) Cash generated from operations (172.82) (346.30) Income taxes (paid)/refund (19.42) (52.91) Net cash flow generated from/ (used in) operating activities (A) (192.24) (399.21) B. Cash flow from investing activities Purchases of property, plant and equipment (including CWIP and capital advances) (1,712.44) (3,287.08) Proceeds from sale of property, plant and equipment 7.68 0.04 Investments in others 1.24 (103.57) Proceeds from redemption / (contribution to) of margin money deposits 420.08 852.25 Interest received 6.63 32.52 Net cash used in investing activities (B) (1,276.81) (2,505.84) C. Cash flow from financing activities Proceeds from issue of fresh equity shares 4.41 30.35 Repayment of related party loan - (32.50) Proceeds/(repayment) of short term borrowings (net) 1 ,608.65 517.20 Proceeds of long-term borrowings 2,808.94 2,741.25 Repayment of long-term borrowings (2,339.94) (352.88) Lease Payments (122.16) (110.88) Interest paid (704.92) (479.78) Net cash from financing activities (C) 1,254.98 2,312.76 Six months ended Particulars
Page 14
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, We bsite : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 Consolidated Statement of Cash Flows for the period and six months ended September 30, 2026 Rs. in Million September 30, 2026 September 30, 2025 (Unaudited) (Unaudited) Six months ended Particulars Net increase / (decrease) in cash and cash equivalents (A+B+C) (214.07) (592.29) Cash and cash equivalents at the beginning of the year 383.37 1,653.59 Cash and cash equivalents at the end of the year 169.30 1,061.30 Reconciliation of cash and cash equivalents with the Consolidated Balance Sheet: Cash and cash equivalents as per Balance Sheet 141.79 1,035.45 Liquid Mutual Funds 27.51 25.85 Cash and cash equivalents at the end of the year* 169.30 1,061.30 * Cash and cash equivalents comprises: Cash on hand 0.53 0.84 Balances with banks - in current accounts 141.26 1,034.61 Liquid Mutual Funds 27.51 25.85 Total 169.30 1,061.30 See accompanying notes to the Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026
Page 15
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 1 2 3 4 Exceptional items - gain / (loss) (net) (Rs. in million) Year ended September 30, 2026 June 30, 2026 Se ptember 30, 2025 September 30, 2026 Septem ber 30, 2025 March 31, 2026 Legal charges related to legacy litigation of subsidiary 1 (17.67) (43.00) - (60.67) (28.70) (45.07) Employees' one-time mutual separation settlement - - - - - (41.47) Gratuity and Compensated absences impact under new Labour Codes - - - - - (12.73) Total (17.67) (43.00) - (60.67) (28.70) (99.27) 1 Expenses relate to legal fees and other associated costs arising from the Prestige litigation regarding the Sputnik vaccine (r efer note 6). 5 Information on Standalone Financial Results (Rs. in million) Particulars Year ended September 30, 2026 June 30, 2026 Se ptember 30, 2025 September 30, 2026 Septem ber 30, 2025 March 31, 2026 Total Income 5,154.19 4,502.58 3,782.23 9,656.77 7,044.90 14,203.89 Profit/(loss) before tax 861.92 512.25 371.01 1,374.17 619.16 212.10 Profit/(loss) after tax 861.92 512.25 371.01 1,374.17 619.16 212.10 6 Claims not acknowledged as debts by the Group 7 Six months ended In terms of Regulation 33 of SEBI ( Listing Obligations and Disclosure Requirements ) Regulations, 2015 ("Listing Requirements") as amended, the Sta tement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 ("Statement") of OneSource Specialty Pharma Limited ('the Pa rent' or 'the Company') and its subsidiaries (together referred to as 'the Group') has been reviewed by the Audit Committee at their meeting held on October 26, 2026 and approved by th e Board of Directors at their meeting held on October 27, 2026. The aforesaid results have been reviewed by the statutory auditor of the Company, who has issued an unmodified report in respect of the limited review for the quarter and six months ended September 30, 2026. The above Statement has been prepared in accordance with the Indian Accounting Standards notified under Section 133 of the Companies Act, 2013 as amen ded, read with relevant rules thereunder and in terms of Listing Requirements, as amended. Currently, this matter is pending before Singapore International Arbitration Centre (SIAC). The Group firmly believes that all claims from Prestig e have no legal merit and therefore all claims are frivolous. Based on the "management approach" as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker ("CODM") evaluates the Group's pe rformance based on an analysis of various performance indicators. The accounting principles used in the preparation of these financial results are consistently appli ed to record revenue and expenditure in individual segments. Effective April 01, 2025, the CODM evaluates the business, including resource allocation and performance assessment as a single segment, i.e. “Cont ract Development and Manufacturing Organization” (CDMO). Accordingly, the disclosures made in the Consolidated Financial Results suffice for compliance with the requ irements of Ind AS 108. The segment information for the Financial year 2025-26 was disclosed for the purpose of comparative disclosure as per Ind AS 34. Particulars Quarter ended Quarter ended Six months ended Biolexis Pte Limited, ('Biolexis') a subsidiary of the Company, has received a claim from Prestige Biopharma Limited ('Prestige'/ 'manufacturing p artner') of USD 136.32 million (Rs. 13,083.99 million) during the year ended March 31, 2023 and additional unsubstantiated claims during the said period, including towards reimbursem ent of expenditure claiming that it suffered loss and damage due to the Contract Manufacturing Agreement to manufacture Sputnik Light Vaccine being terminated b y Biolexis. Further Biolexis denies liability, citing Prestige’s lack of readiness and approval of the manufacturing plant and lack of raw material supply readiness. Biolexis has already taken legal recourse through its external legal counsel to refute all the claims as false, baseless, and misconceived and has sought a 100% refund of the Capacity f ee of USD 13.62 million (Rs.1,307.25 million) which was paid to Prestige guaranteeing the prompt refund of the Capacity fee paid to Prestige in case no manufacturing occurs within the agreed timelines. During the previous year ended March 31, 2026, the Company has capitalised borrowing costs attributable to qualifying assets classified under Capit al Work-in-Progress (CWIP), in accordance with Ind AS 23, Borrowing Costs. The determination of borrowing costs eligible for capitalisation was completed based on detailed project-level assessments undertaken as part of t he year-end closing process, including technical and operational evaluations of the activities necessary to prepare the assets for their intended use. Given the long gestation p eriod and complexity of the projects, such assessments are concluded upon completion of the requisite evaluations. Accordingly, borrowing costs amounting to Rs. 186.09 million have been capitalised for the year ended March 2026 (Rs. 103.40 millions relates to the p revious quarters) resulting in a corresponding reduction in finance costs for the year ended March 31, 2026 and an increase in Capital Work-in-Progress.
Page 16
OneSource Specialty Pharma Limited Registered Office : Unit no. 902, "Cyber One" situated at Plot no. 4 & 6, Sector 30A, Vashi, Navi Mumbai-400703 Corporate Office : Star 1, Opp IIM Bangalore, Bilekahalli, Bannerghatta Road, Bangalore - 560076, India CIN: L74140MH2007PLC432497, Website : https://www.onesourcecdmo.com, Mail: info@onesourcecdmo.com Statement of Unaudited Consolidated Financial Results for the quarter and six months ended September 30, 2026 8 9 For and on behalf of Board of Directors of OneSource Specialty Pharma Limited Neeraj Sharma Managing Director DIN : 09402652 Place : Bengaluru Date : October 27, 2026 Figures for the previous periods, wherever necessary, have been regrouped/reclassified to conform to the current period's presentation. The Ministry of Corporate Affairs (MCA), vide its notification dated 13 August 2025, amended Ind AS 1 with respect to breach of covenants. Under the ame nded requirements the relief relating to “covenant waivers obtained after the balance sheet date but before the date of financial statements issuance” has been withdrawn f or accounting periods beginning on or after 1 April 2026, and the amendment is required to be applied retrospectively to the comparative period ended 31 March 202 6. Pursuant to the aforesaid amendment, the Group has, in these financial results, reclassified its comparative borrowings as at 31 March 2026 amountin g to Rs. 3,676.84 million from non-current financial liabilities to current financial liabilities, considering that waiver for two of its borrowing facilities was obtained afte r March 31, 2026 but before the issuance of the financial statements for the year ended March 31, 2026. This reclassification impacts only the presentation of said borrowings and has no effect on total borrowings, net worth, profit after tax, earnings p er share or cash flows of the Group, or on the presentation of its audited financial statements as on and for the year ended March 31, 2026. Neeraj Sharma Digitally signed by Neeraj Sharma Date: 2026.10.27 09:05:47 +05'30'